NCT06295094View on ClinicalTrials.gov

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Gastric CancerChemotherapy, AdjuvantPeritoneal MetastasesMinimally Invasive Surgical Procedures
Interventions
DRUG

Cisplatin

10.5 mg/m2 body surface in 150ml saline

DRUG

Doxorubicin

2.1 mg/m2 body surface in 50ml saline

Trial Locations (5)

5000

Odense University Hospital, Odense C

91010

City of Hope, Duarte

Unknown

University Hospital Lille, Lille

Charité, University of Berlin, Berlin

Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

lead

Odense University Hospital

OTHER

NCT06295094 - The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. | Biotech Hunter | Biotech Hunter